EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).

The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by:

1. improving clinical periodontal parameters and, 2. improving the salivary SOD levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cyclooxygenase Two Inhibitors Etoricoxib Mouth Diseases Periodontal Diseases Periodontitis Saliva Stomatognathic Diseases Superoxide Dismutase

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Tatyasaheb kore Dental College And Research Centre

Kolhāpur, Maharashtra, 416137, India

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Forty patients with chronic generalized periodontitis

Exclusion criteria

with system illnesses, allergies, pregnancy, history of any drug intake and periodontal treatment in past 6 months.

Treatment and study plan

Etoricoxib

Drug

Other names: Nucoxia, Arcoxia

Primary outcomes

change from baseline in salivary SOD level

Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Tatyasaheb Kore Dental College

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2013
Study completion: 2013
First posted: May 29, 2014
Registry last updated: May 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed